James B. Breitmeyer M.D., Ph.D.
Dr. Breitmeyer has served as a member of our board of directors since March 2014. He currently serves as President of Bavarian Nordic, Inc., a late-stage biotechnology company focused on developing and producing novel immunotherapy candidates for the treatment of life-threatening diseases. He is also Executive Vice President of Bavarian A/S, a multinational corporation headquartered in Denmark, that is highly specialized in the research, development and manufacturing of vaccines and immunotherapy regimens for biodefense, infectious diseases and oncology. He previously served as the acting Chief Medical Officer of Zogenix Inc. in an advisory capacity, the Executive Vice President of Development and Chief Medical Officer of Cadence Pharmaceuticals Inc., and the Chief Medical Officer of Applied Molecular Evolution Inc., a wholly-owned subsidiary of Eli Lilly and Co. Dr. Breitmeyer has also served as President and Chief Executive Officer of the Harvard Clinical Research Institute and held a variety of positions at Serono Laboratories Inc. Prior to Serono Laboratories, Dr. Breitmeyer served as a Consultant to Immunogen Inc., and held clinical and teaching positions at the Dana Farber Cancer Institute and Harvard Medical School. Dr. Breitmeyer holds a BA in Chemistry from the University of California, Santa Cruz and an M.D. and Ph.D. from Washington University School of Medicine and is Board Certified in Internal Medicine and Oncology.